Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

How can we stamp out high-risk myeloma?

Rahul Banerjee, Joseph R. Mikhael

Blood (2024) 143 (20): 2015–2016.

https://doi.org/10.1182/blood.2024024140

Published: 2024

Journal Articles

Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma - a National All-Payer Claims Database Study

Rahul Banerjee, Nina Kim, Monal Kohli, Laura Hester, Emily Achter, Jessica Fowler, Emeka Umeh, Dee Lin, Gideon Aweh, Dina Gifkins, Sian Walker, Bingcao Wu

Blood (2023) 142 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2023-178908

Published: 2023

Journal Articles

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Rahul Banerjee, Andrew J. Cowan, Marivel Chavez-Ortega, Paul A Carpenter, Masumi Ueda Oshima, Rachel B. Salit, Phuong T Vo, Catherine J. Lee, Rohtesh S. Mehta, Nicole M. Kuderer, Veena Shankaran, Stephanie J. Lee, Christopher T. Su

Blood (2023) 142 (Supplement 1): 2386.

https://doi.org/10.1182/blood-2023-174554

Published: 2023

Journal Articles

Treatment and Coaching Experience of Individuals with Relapsed/Refractory Multiple Myeloma: Qualitative Insights during Treatment with Isatuximab

Kelly Brassil, Rahul Banerjee, Austin Barr, Trenton Grossfeld, Andrew J. Cowan, Elisabet E. Manasanch

Blood (2023) 142 (Supplement 1): 7439.

https://doi.org/10.1182/blood-2023-190950

Published: 2023

Journal Articles

Effectiveness of Cross-Platform Online Activities to Reinforce Physician Competence Around BCMA-Directed Therapies in Multiple Myeloma

Elizabeth J. Heller, Keira P Smith, Lyn F Brook, Eden EED Maack, Rahul Banerjee

Blood (2023) 142 (Supplement 1): 7285.

https://doi.org/10.1182/blood-2023-181839

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Rawan Atallah, Md Saiful Islam Saif, Danai Dima, Anuj Shrestha, Faiz Anwer, Muhammad Umair Mushtaq, Forat Lutfi, Leyla Shune, Hamza Hashmi, Siddhartha Ganguly, Joseph P McGuirk, Shebli Atrash, Al-Ola Abdallah, Rahul Banerjee, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2023-181218

Published: 2023

Journal Articles

Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians

Rahul Banerjee, Gurbakhash Kaur, Bo Wang, Larry D. Anderson, Jr., Georgia McCaughan, Andrew J. Cowan, S. Vincent Rajkumar

Blood (2023) 142 (Supplement 1): 5073.

https://doi.org/10.1182/blood-2023-173772

Published: 2023

Journal Articles

Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma

Fieke W Hoff, Rahul Banerjee, Adeel Khan, Georgia McCaughan, Xiaoliang (Wendy) Wang, James Roose, Larry D. Anderson, Jr., Andrew J. Cowan, Vincent Rajkumar, Gurbakhash Kaur

Blood (2023) 142 (Supplement 1): 544.

https://doi.org/10.1182/blood-2023-178950

Published: 2023

Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Blood (2023) 142 (Supplement 1): 3509.

https://doi.org/10.1182/blood-2023-173202

Published: 2023

Journal Articles

Evaluating Patient-Reported Outcomes and Wearable Data Among Individuals with Relapsed/Refractory Multiple Myeloma

Rahul Banerjee, Kelly Brassil, Trenton Grossfeld, Austin Barr, Andrew J. Cowan

Blood (2023) 142 (Supplement 1): 5191.

https://doi.org/10.1182/blood-2023-190536

Published: 2023

Journal Articles

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji Kunnathu Kumar, Sagar Lonial, Bart Barlogie, Brian GM Durie, Saad Z Usmani, Antje Hoering, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 1066.

https://doi.org/10.1182/blood-2023-181744

Published: 2023

Journal Articles

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Emily C Liang, Erik L Kimble, Aya Albittar, Jennifer J. Huang, Andrew J Portuguese, Aiko Torkelson, Delaney Kirchmeier, Abigail Chutnik, Barbara Pender, Sylvain Simon, Tony Chour, Evan W. Newell, Rahul Banerjee, David G Maloney, Alexander Spicer, Juho Jalkanen, Alexandre V Hirayama, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 4860.

https://doi.org/10.1182/blood-2023-173152

Published: 2023

Journal Articles

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Kelsey H. Natsuhara, Chiung-Yu Huang, Jennifer Knoche, Shagun Arora, Alfred Chung, Thomas Martin, Jeffrey L. Wolf, Sandy W. Wong, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 7910–7912.

https://doi.org/10.1182/blood-2022-155906

Published: 2022

Journal Articles

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Kevin R Reyes, Yen-Chun Liu, Chiung-Yu Huang, Rahul Banerjee, Thomas Martin, Nina Shah, Sandy W. Wong, Jeffrey L. Wolf, Shagun Arora, Alfred Chung

Blood (2022) 140 (Supplement 1): 617–619.

https://doi.org/10.1182/blood-2022-160401

Published: 2022

Journal Articles

Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

Jordan Ciuro, Elizabeth Henry, Nadine Housri, Rahul Banerjee, Elizabeth A Brem, Taylor Brooks, Ben A. Derman, Brian T. Hill, Craig C Hofmeister, Matthew A. Lunning, Matthew J. Matasar, Tycel J. Phillips, Sarah C. Rutherford, Saurabh Zanwar, Lauren E Lee

Blood (2022) 140 (Supplement 1): 13180–13181.

https://doi.org/10.1182/blood-2022-167959

Published: 2022

Journal Articles

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Kevin R. Reyes, Chiung-Yu Huang, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 5105–5107.

https://doi.org/10.1182/blood-2022-160362

Published: 2022

Journal Articles

Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy

Aneeqa A Zafar, Chiung-Yu Huang, Mimi Lo, Jen Knoche, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Nina Shah, Rahul Banerjee

Blood (2022) 140 (Supplement 1): 5218–5220.

https://doi.org/10.1182/blood-2022-162122

Published: 2022

Journal Articles

Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation

Rahul Banerjee, Ann A. Lazar, Chloe Ryan, Jen Knoche, Kelly Jean Brassil, Lindsey Jackson, Dhiren Patel, Mimi Lo, Shagun Arora, Alfred Chung, Sandy W. Wong, Jeffrey L. Wolf, Thomas Martin, Anand Dhruva, Nina Shah

Blood (2021) 138 (Supplement 1): 4023.

https://doi.org/10.1182/blood-2021-147125

Published: 2021

NARROW

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

How can we stamp out high-risk myeloma?

Evolving Real-World Characteristics and Step-up Dosing Among Early Initiators of Teclistamab for Multiple Myeloma - a National All-Payer Claims Database Study

Financial Toxicity and Time Toxicity in Multiple Myeloma: Prevalence, Predictors, and Impact on QOL

Treatment and Coaching Experience of Individuals with Relapsed/Refractory Multiple Myeloma: Qualitative Insights during Treatment with Isatuximab

Effectiveness of Cross-Platform Online Activities to Reinforce Physician Competence Around BCMA-Directed Therapies in Multiple Myeloma

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Trends in Access to Cellular Therapies in Multiple Myeloma (TACTUM): Perspectives of Treating Versus Referring Physicians

Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians

Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Evaluating Patient-Reported Outcomes and Wearable Data Among Individuals with Relapsed/Refractory Multiple Myeloma

Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211

Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress

Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy

Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only